The Canadian Underage Substance Use Prevention Trial (CUSP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04198974 |
Recruitment Status : Unknown
Verified December 2019 by Patricia Conrod, St. Justine's Hospital.
Recruitment status was: Recruiting
First Posted : December 13, 2019
Last Update Posted : December 17, 2019
|
Tracking Information | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | December 4, 2019 | ||||||||||||||||||||||||
First Posted Date ICMJE | December 13, 2019 | ||||||||||||||||||||||||
Last Update Posted Date | December 17, 2019 | ||||||||||||||||||||||||
Actual Study Start Date ICMJE | December 1, 2019 | ||||||||||||||||||||||||
Estimated Primary Completion Date | December 2021 (Final data collection date for primary outcome measure) | ||||||||||||||||||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||||||||||||||||||
Original Primary Outcome Measures ICMJE |
|
||||||||||||||||||||||||
Change History | |||||||||||||||||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||||||||||||||||
Original Secondary Outcome Measures ICMJE |
|
||||||||||||||||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||||||||||
Descriptive Information | |||||||||||||||||||||||||
Brief Title ICMJE | The Canadian Underage Substance Use Prevention Trial | ||||||||||||||||||||||||
Official Title ICMJE | The Canadian Underage Substance Use Prevention Trial | ||||||||||||||||||||||||
Brief Summary | Despite having made some strides with respect to reducing adolescent drinking rates, illicit substance use and substance use disorders (SUDs) remain significantly above national targets for health promotion and disease prevention in Canada and the United States. Now, more than ever, there is a pressing need for effective substance abuse prevention in Canada, particularly for those most at risk of developing substance use problems including prescription drug misuse. Clearly, new approaches to prevention (with lower numbers needed to treat) are needed and which translate new research on addiction vulnerability to personalised prevention and early intervention. The PreVenture Program involves brief cognitive-behavioural interventions targeting personality traits from a neurocognitive perspective. While the personality-targeted approach has been shown to be effective in reducing most substance use behaviors, it has yet to be evaluated for its impact on uptake of prescription drug misuse in adolescents. The Canadian Underage Substance use Prevention (CUSP) Trial aims to evaluate the long-term effects of a personality-targeted school-based prevention program on delaying the onset of drug and alcohol use in adolescence over three years across Canada. This is a hybrid effectiveness [E] and implementation-facilitation [IF] trial on delaying the onset of drug and alcohol use in adolescence. In the [E] part, the effects of a personalized prevention program will be tested against usual school-based prevention curricula. PreVenture is delivered through a TtT implementation model with or without [IF], e.g. with ongoing supervision and web-based support. The [IF] package is designed to support long-term sustainability of PreVenture after a community accesses PreVenture training. | ||||||||||||||||||||||||
Detailed Description | Aim: To evaluate the long-term effects of the PreVenture program on delaying the onset of drug and alcohol use in adolescence when delivered through a train-the-trainer (TtT) implementation model. Questions: This is a hybrid effectiveness [E] and implementation-facilitation [IF] trial on delaying the onset of drug and alcohol use in adolescence. In the [E] part, the effects of a personalized prevention program will be tested against usual school-based prevention curricula. PreVenture is delivered through a TtT implementation model with or without [IF], e.g. with ongoing supervision and web-based support. The [IF] package is designed to support long-term sustainability of PreVenture after a community accesses PreVenture training. [E] questions: Does the personalized intervention delay the onset and reduce the severity of problem substance use among secondary school students when schools are trained through a TtT model (primary)? Does the intervention impact the onset and frequency of binge drinking, cannabis and illicit drug use, and uptake of non-medical prescription drug use at (i) one year and (ii) two years post-intervention (secondary)? What are the factors which impact the delay of onset and reduction of severity? [IF] questions: What are the best conditions under which the program implementation is sustained to a high quality from one year to the next? What are the costs and potential economic benefits of the intervention with and without additional implementation facilitation? Design: Three sites (NS; ON; BC) will participate in the trial. Each site will recruit 9 high schools randomized to one of three intervention conditions:
Each school will screen all assenting grade 10 students (N=150 per school) in 2019 (Cohort 2 followed up until 2021), 2020 (Cohort 3 followed up until 2021) and 2021 (Cohort 4 no follow-up), which will result in approximately 4,050 students screened across 27 schools in Canada each year totaling 12,150 students over 3 years. [Cohort 1 is training-only in 2018] All 4050 students will be invited to participate in the trial each year and will be followed annually to facilitate coordination of assessments at the school level and to reduce any stigma to targeted youth. Youth who assent to being randomized to an intervention condition and who score above the personality threshold will be considered the Intent-to-Treat [ITT] sample, regardless of whether or not the school managed to deliver the intervention. The whole grade will be followed to assess secondary outcomes at the whole grade level as reported in Conrod et al, 2013. The PreVenture program is a personality targeted prevention program designed to help youth understand the target personality trait and develop adaptive coping strategies for managing that trait using motivational and cognitive restructuring techniques. Four personality-specific motivational pathways to substance misuse are targeted hopelessness (HOP), anxiety sensitivity (AS), impulsivity (IMP) and sensation seeking (SS). PreVenture involves 2 90-minute group sessions, with one week separating each session. The interventions are conducted using structured manuals that incorporate psycho-educational, motivational enhancement (MET), and cognitive-behavioural (CBT) therapy components, and include real life 'scenarios' shared by local youth with similar personality profiles. Main Hypotheses: [E] primary outcome: PreVenture will result in less severity of substance use problems as measured by the CRAFFT score after 12- and 24-month follow-up (comparison of both arms with PreVenture against treatment as usual using Cohort 2 in all three conditions) [E] secondary outcome: PreVenture will result in lower prevalence of binge drinking, lowered frequency of cannabis use, other illicit drug use and non-medical prescription drug use after 12- and 24-month follow-ups (comparison of both arms with PreVenture against treatment as usual using Cohort 2 in all three conditions) [IF] primary outcome: In the PreVenture group with implementation-facilitation, the rate of successful interventions (less severity on CRAFFT score) after 12-month follow-up is higher than in the PreVenture group without implementation-facilitation (comparison of 12-month results of Cohort 3 between both conditions) [IF] secondary outcome: In the PreVenture group with implementation-facilitation, the rate of interventions in Year 4 after the start of PreVenture interventions is higher than in the PreVenture group without implementation-facilitation (comparison of Cohort 4 between both conditions) Data analyses strategy for [E]: The core data for exploring effectiveness will be in Cohort 2, followed up for 24 months. This allows for the use of growth models, which can model intra-individual change over time. The dependent variables for these models change, may be dichotomous (e.g., onset of substance use: yes/no), ordinal, expressing counts or have interval properties (for example, the CRAFFT scale can be used as an ordinal or count variable - i.e. this poses a number of problems - but has also been used as a scale with interval scale properties). Different scale types require different types of regression analyses to be used in growth modelling (i.e., linear regression, logistic regression, Poisson regression, etc.). For the CRAFFT score, three aspects require consideration:
For the primary outcome, the following statistical procedures will be used (ITT analyses):
For the secondary hypotheses, similar procedures will be used, with the specific regression type to be determined by the dependent variable. In addition to ITT analyses, sensitivity analyses with different assumptions on missing values will be conducted. The investigators will also test if the effect of PreVenture is significant in each of the two time points (i.e., not only for the combined time points). Other analyses will explore different influencing factors on the effectiveness of PreVenture and these analyses will be conducted in the same framework, adding different independent variables. The investigators will combine this framework with a latent framework (latent growth analyses); to separate groups with different trajectories, and will model influences on these separate trajectories. Data analysis strategy for [IF]: It is important for an intervention such as PreVenture, which has proven efficacy under certain conditions, to show effectiveness in the real world under less optimal conditions, and to measure the various impacts on effectiveness. Accordingly, one of the experimental conditions systematically varies implementation conditions by introducing three additional components: a) Involvement of local youth in promoting the program, b) ongoing coaching/supervision sessions for group facilitators, c) access to easy-to-use performance metrics. The impact of facilitation will be tested in the following primary implementation hypothesis:
There will be more analyses to explore the implementation facilitation. One key will be measurement of the fidelity and quality of implementation, and the investigators will be using a specifically developed measure, the PreVenture Intervention Fidelity and Adherence (PIFA) scale, for the latter. Overall, the analyses will include the infrastructure, the number of interventions produced, and the success rates of these interventions. Economic considerations:
|
||||||||||||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||||||||||||
Study Phase ICMJE | Not Applicable | ||||||||||||||||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Hybrid effectiveness/implementation randomized control trial Masking: Single (Outcomes Assessor)Masking Description: The evaluation team will be blinded to the intervention conditions until 24 months Primary Purpose: Prevention
|
||||||||||||||||||||||||
Condition ICMJE |
|
||||||||||||||||||||||||
Intervention ICMJE |
|
||||||||||||||||||||||||
Study Arms ICMJE |
|
||||||||||||||||||||||||
Publications * |
|
||||||||||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||||||||||
Recruitment Information | |||||||||||||||||||||||||
Recruitment Status ICMJE | Unknown status | ||||||||||||||||||||||||
Estimated Enrollment ICMJE |
12500 | ||||||||||||||||||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||||||||||||||||||
Estimated Study Completion Date ICMJE | June 2022 | ||||||||||||||||||||||||
Estimated Primary Completion Date | December 2021 (Final data collection date for primary outcome measure) | ||||||||||||||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria: - Students that do not have either active parental consent or youth assent (depending on local site requirements) will not be eligible to participate in the survey or PreVenture |
||||||||||||||||||||||||
Sex/Gender ICMJE |
|
||||||||||||||||||||||||
Ages ICMJE | 15 Years to 16 Years (Child) | ||||||||||||||||||||||||
Accepts Healthy Volunteers ICMJE | Yes | ||||||||||||||||||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||||||||||||
Listed Location Countries ICMJE | Canada | ||||||||||||||||||||||||
Removed Location Countries | |||||||||||||||||||||||||
Administrative Information | |||||||||||||||||||||||||
NCT Number ICMJE | NCT04198974 | ||||||||||||||||||||||||
Other Study ID Numbers ICMJE | CUSP Trial | ||||||||||||||||||||||||
Has Data Monitoring Committee | Yes | ||||||||||||||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||||||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||||||||||||||||
Current Responsible Party | Patricia Conrod, St. Justine's Hospital | ||||||||||||||||||||||||
Original Responsible Party | Same as current | ||||||||||||||||||||||||
Current Study Sponsor ICMJE | St. Justine's Hospital | ||||||||||||||||||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||||||||||||||||||
Collaborators ICMJE |
|
||||||||||||||||||||||||
Investigators ICMJE |
|
||||||||||||||||||||||||
PRS Account | St. Justine's Hospital | ||||||||||||||||||||||||
Verification Date | December 2019 | ||||||||||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |